Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Nov;32(5):557–561. doi: 10.1111/j.1365-2125.1991.tb03951.x

Theophylline therapy inhibits neutrophil and mononuclear cell chemotaxis from chronic asthmatic children.

A Condino-Neto 1, M M Vilela 1, E C Cambiucci 1, J D Ribeiro 1, A A Guglielmi 1, L A Magna 1, G De Nucci 1
PMCID: PMC1368630  PMID: 1659436

Abstract

1. Theophylline is commonly used to relieve symptoms of chronic asthma. Since neutrophil and mononuclear cell activation are associated with late phase asthmatic reactions, effects of theophylline on these cells may be of importance. 2. In the present investigation we compared neutrophil and mononuclear cell chemotaxis from chronic asthmatic children during and after theophylline therapy. 3. Thirty patients were recruited for the study. Each patient received theophylline orally for 10 days. The theophylline dose was 20 mg kg-1 day-1 given in four divided doses. On the tenth day, blood was collected into heparinized (100 u ml-1) and siliconized tubes 2 h after the last theophylline dose for chemotactic assays, cAMP and theophylline plasma determinations. When clinical conditions allowed, theophylline was discontinued for 7 days and the chemotactic assays, cAMP and theophylline plasma concentrations repeated. Serum complement and IgE levels were also determined. 4. Theophylline therapy clearly inhibited both spontaneous and stimulated neutrophil and mononuclear cell chemotaxis. Twenty-seven patients had therapeutic plasma concentrations of theophylline (5-20 micrograms ml-1). Discontinuation of theophylline therapy caused a significant decrease in plasma cAMP levels (44 and 31 pmol ml-1 respectively during and after treatment, n = 30, P less than 0.001). 5. The inhibition of neutrophil and mononuclear cell migration by theophylline therapy in chronic asthmatic children may be beneficial for the control of the inflammatory response observed in these patients.

Full text

PDF
557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BOYDEN S. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med. 1962 Mar 1;115:453–466. doi: 10.1084/jem.115.3.453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BUTCHER R. W., SUTHERLAND E. W. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem. 1962 Apr;237:1244–1250. [PubMed] [Google Scholar]
  3. Bergstrand H. Phosphodiesterase inhibition and theophylline. Eur J Respir Dis Suppl. 1980;109:37–44. [PubMed] [Google Scholar]
  4. Bourne H. R., Lehrer R. I., Cline M. J., Melmon K. L. Cyclic 3',5'-adenosine monophosphate in the human lukocyte: synthesis, degradation, andeffects n neutrophil candidacidal activity. J Clin Invest. 1971 Apr;50(4):920–929. doi: 10.1172/JCI106564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bourne H. R., Melmon K. L., Lichtenstein L. M. Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science. 1971 Aug 20;173(3998):743–745. doi: 10.1126/science.173.3998.743. [DOI] [PubMed] [Google Scholar]
  6. Chikazawa S., Nunoi H., Endo F., Matsuda I., Honda M. Hyperimmunoglobulin-E-associated recurrent infection syndrome accompanied by chemotactic inhibition of polymorphonuclear leukocytes and monocytes. Pediatr Res. 1984 Apr;18(4):365–369. doi: 10.1203/00006450-198404000-00012. [DOI] [PubMed] [Google Scholar]
  7. Fischer T. J., Gard S. E., Rachelefsky G. S., Klein R. B., Borut T. C., Stiehm E. R. Monocyte chemotaxis under agarose: defects in atopic disease, aspirin therapy, and mucocutaneous candidiasis. Pediatr Res. 1980 Mar;14(3):242–246. doi: 10.1203/00006450-198003000-00013. [DOI] [PubMed] [Google Scholar]
  8. Fredholm B. B. Theophylline actions on adenosine receptors. Eur J Respir Dis Suppl. 1980;109:29–36. [PubMed] [Google Scholar]
  9. Ghazanshahi S., Townley R., Chaperone E., Villacorte G. T and B lymphocyte rosettes in bronchial asthma. Ann Allergy. 1976 May;36(5):324–329. [PubMed] [Google Scholar]
  10. Gilman A. G. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615–649. doi: 10.1146/annurev.bi.56.070187.003151. [DOI] [PubMed] [Google Scholar]
  11. Grove D. I., Burston T. O., Wellby M. L., Ford R. M., Forbes I. J. Humoral and cellular immunity in asthma. J Allergy Clin Immunol. 1975 Mar;55(3):152–163. doi: 10.1016/0091-6749(75)90011-1. [DOI] [PubMed] [Google Scholar]
  12. Hill H. R., Estensen R. D., Hogan N. A., Quie P. G. Severe staphylococcal disease associated with allergic manifestations, hyperimmunoglobulinemia E, and defective neutrophil chemotaxis. J Lab Clin Med. 1976 Nov;88(5):796–806. [PubMed] [Google Scholar]
  13. Hill H. R., Quie P. G. Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections. Lancet. 1974 Feb 9;1(7850):183–187. doi: 10.1016/s0140-6736(74)92493-3. [DOI] [PubMed] [Google Scholar]
  14. Hill H. R., Williams P. B., Krueger G. G., Janis B. Recurrent staphylococcal abscesses associated with defective neutrophil chemotaxis and allergic rhinitis. Ann Intern Med. 1976 Jul;85(1):39–43. doi: 10.7326/0003-4819-85-1-39. [DOI] [PubMed] [Google Scholar]
  15. Johansson S. G. In vitro diagnosis of reagin-mediated allergic diseases. Allergy. 1978 Dec;33(6):292–298. doi: 10.1111/j.1398-9995.1978.tb01554.x. [DOI] [PubMed] [Google Scholar]
  16. Kammer G. M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today. 1988 Jul-Aug;9(7-8):222–229. doi: 10.1016/0167-5699(88)91220-0. [DOI] [PubMed] [Google Scholar]
  17. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  18. Martínez Cairo-Cueto S., Espinosa-Ayala J., López-Román M., Lugo J. C. Defective chemotaxis of PMN cells of patients with bronchial asthma. Arch Invest Med (Mex) 1981;12(4):505–515. [PubMed] [Google Scholar]
  19. Nielson C. P., Crowley J. J., Cusack B. J., Vestal R. E. Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):660–667. doi: 10.1016/0091-6749(86)90086-2. [DOI] [PubMed] [Google Scholar]
  20. Nielson C. P., Crowley J. J., Morgan M. E., Vestal R. E. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3',5'-adenosine monophosphate. Am Rev Respir Dis. 1988 Jan;137(1):25–30. doi: 10.1164/ajrccm/137.1.25. [DOI] [PubMed] [Google Scholar]
  21. Norman M. E., Gall E. P., Taylor A., Laster L., Nilsson U. R. Serum complement profiles in infants and children. J Pediatr. 1975 Dec;87(6 Pt 1):912–916. doi: 10.1016/s0022-3476(75)80904-8. [DOI] [PubMed] [Google Scholar]
  22. Ou C. N., Frawley V. L., Buffone G. J. Optimization of EMIT reagent system using a COBAS-BIO centrifugal analyzer. J Anal Toxicol. 1981 Sep-Oct;5(5):249–252. doi: 10.1093/jat/5.5.249. [DOI] [PubMed] [Google Scholar]
  23. Polson J. B., Krzanowski J. J., Goldman A. L., Szentivanyi A. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol. 1978 Sep-Oct;5(5):535–539. doi: 10.1111/j.1440-1681.1978.tb00707.x. [DOI] [PubMed] [Google Scholar]
  24. Robinson C., Holgate S. T. Mast cell-dependent inflammatory mediators and their putative role in bronchial asthma. Clin Sci (Lond) 1985 Feb;68(2):103–112. doi: 10.1042/cs0680103. [DOI] [PubMed] [Google Scholar]
  25. Rose F. R., Hirschhorn R., Weissmann G., Cronstein B. N. Adenosine promotes neutrophil chemotaxis. J Exp Med. 1988 Mar 1;167(3):1186–1194. doi: 10.1084/jem.167.3.1186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Scordamaglia A., Ciprandi G., Ruffoni S., Caria M., Paolieri F., Venuti D., Canonica G. W. Theophylline and the immune response: in vitro and in vivo effects. Clin Immunol Immunopathol. 1988 Aug;48(2):238–246. doi: 10.1016/0090-1229(88)90087-6. [DOI] [PubMed] [Google Scholar]
  27. Ternowitz T., Herlin T. Defective monocyte and polymorphonuclear leukocyte chemotaxis and clinical characteristics in atopic dermatitis. Arch Dermatol Res. 1986;278(6):454–459. doi: 10.1007/BF00455163. [DOI] [PubMed] [Google Scholar]
  28. Tovey K. C., Oldham K. G., Whelan J. A. A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. Clin Chim Acta. 1974 Nov 8;56(3):221–234. doi: 10.1016/0009-8981(74)90133-8. [DOI] [PubMed] [Google Scholar]
  29. Valerius N. H. Chemotaxis of neutrophil granulocytes. Measurement, cell biology and clinical significance. Dan Med Bull. 1984 Dec;31(6):458–474. [PubMed] [Google Scholar]
  30. Weidner N., Dietzler D. N., Ladenson J. H., Kessler G., Larson L., Smith C. H., James T., McDonald J. M. A clinically applicable high-pressure liquid chromatographic method for measurement of serum theophylline, with detailed evaluation of interferences. Am J Clin Pathol. 1980 Jan;73(1):79–86. doi: 10.1093/ajcp/73.1.79. [DOI] [PubMed] [Google Scholar]
  31. Weinberger M. The pharmacology and therapeutic use of theophylline. J Allergy Clin Immunol. 1984 May;73(5 Pt 1):525–540. doi: 10.1016/0091-6749(84)90505-0. [DOI] [PubMed] [Google Scholar]
  32. Weissmann G., Dukor P., Zurier R. B. Effect of cyclic AMP on release of lysosomal enzymes from phagocytes. Nat New Biol. 1971 Jun 2;231(22):131–135. doi: 10.1038/newbio231131a0. [DOI] [PubMed] [Google Scholar]
  33. Weth G., Koch H., Haubitz J. Verhalten des Second Messenger cAMP im Status asthmaticus vor und nach Gabe von Theophyllin-Ethylendiamin. Arzneimittelforschung. 1985;35(12):1859–1862. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES